JPO issues patent to NeurogesX NGX-1998
The patent is entitled Methods and Compositions for Administration of TRPV1 Agonists. The patent which covers formulation, system, and kit claims will remain in effect in Japan until
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.
Perceptive Informatics, PAREXEL’s technology subsidiary, developed the fully-integrated eClinical platform. PAREXEL chief operating officer Mark Goldberg said with the availability of PAREXEL MyTrials, users will have a single